fd2

Funding is a core element of ERDERA’s strategy to transform rare disease research in Europe. Its mission is to bridge gaps in scientific knowledge, foster international collaborations, and deliver tangible benefits to millions of patients affected by rare diseases across Europe and beyond.

ERDERA Funding

By pooling resources from the regional/national funding agencies, the EC, the private sector organisations, and philanthropic foundations, ERDERA drives forward groundbreaking research that has the potential to transform lives.

ERDERA’s funding research strategy is built upon a diversity of calls: Joint Transnational Calls, Clinical Trial Calls and the Networking Support Scheme. The topics of these calls are selected by gap analysis according to the needs of the rare disease community gathered from the recommendations of the ERDERA’s advisory and governing bodies.

icon-joint-transnational-call

Joint Transnational Calls

Supports interdisciplinary research to address identified gaps. These calls foster cross-border collaboration and align with the strategic priorities of the rare disease community.

icon-networking-support-scheme

Plays a crucial role in building the research ecosystem by fostering knowledge sharing across national and international actors, attracting underrepresented regions, engaging young researchers, and strengthening the involvement of patient organisations.

icon-clinical-trias-call

Clinical Trial Call

Funds controlled clinical research studies undertaken in humans to establish or confirm the safety and effectiveness of therapeutic interventions. These will benefit from ERDERA support for regulatory and methodological aspects.

Active & Upcoming Calls

icon-networking-support-scheme
Open call

Networking Support Scheme

icon-clinical-trias-call
Upcoming call

Clinical Trial Call 2026

erdera’s funding projects AND EVENTS

Last Activities

icon-networking-support-scheme

CureDravet2

The gene therapy pipeline is intransigently linked to vector efficacy. Due to a paucity of vectors capable of harboring large expression cassettes, several rare diseases have little hope of being targets
icon-joint-transnational-call

CureDravet

The gene therapy pipeline is intransigently linked to vector efficacy. Due to a paucity of vectors capable of harboring large expression cassettes, several rare diseases have little hope of being targets

You might also be interested in

ERDERA will launch its Clinical Trial Call 2026 (ECTC) on 1 July 2026, supporting multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.
Pre-announcement describing scope, eligibility and indicative timeline for the ERDERA Clinical Trial Call 2026, expected to open on 1 July 2026.
Budget example showing low and high cost ranges for a Phase 1 rare disease clinical trial with twenty subjects.